Guided Therapeutics Return on Tangible Equity 2010-2023 | GTHP
Current and historical return on tangible equity values for Guided Therapeutics (GTHP) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Guided Therapeutics Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2023-12-31 | $-0.00B | $-0.00B | 114.29% |
| 2023-09-30 | $-0.01B | $-0.00B | 184.62% |
| 2023-06-30 | $-0.01B | $-0.00B | 200.00% |
| 2023-03-31 | $-0.01B | $-0.00B | 133.33% |
| 2022-12-31 | $-0.01B | $-0.00B | 117.65% |
| 2022-09-30 | $-0.00B | $-0.00B | 84.21% |
| 2022-06-30 | $-0.00B | $-0.01B | 57.14% |
| 2022-03-31 | $-0.00B | $-0.01B | 60.00% |
| 2021-12-31 | $-0.00B | $-0.01B | 52.17% |
| 2021-09-30 | $0.00B | $-0.01B | 0.00% |
| 2021-06-30 | $0.00B | $-0.01B | -21.05% |
| 2021-03-31 | $-0.00B | $-0.01B | 32.65% |
| 2020-12-31 | $0.00B | $-0.01B | 0.00% |
| 2020-09-30 | $-0.00B | $-0.01B | 6.90% |
| 2020-06-30 | $-0.00B | $-0.02B | 19.35% |
| 2020-03-31 | $0.00B | $-0.01B | -6.15% |
| 2019-12-31 | $-0.00B | $-0.02B | 11.43% |
| 2019-09-30 | $-0.01B | $-0.02B | 34.78% |
| 2019-06-30 | $-0.01B | $-0.02B | 43.08% |
| 2019-03-31 | $-0.00B | $-0.02B | 6.67% |
| 2018-12-31 | $0.00B | $-0.02B | 0.00% |
| 2018-09-30 | $-0.00B | $-0.01B | 24.62% |
| 2018-06-30 | $-0.01B | $-0.01B | 31.75% |
| 2018-03-31 | $-0.01B | $-0.02B | 61.02% |
| 2017-12-31 | $-0.01B | $-0.02B | 80.00% |
| 2017-09-30 | $-0.01B | $-0.01B | 50.00% |
| 2017-06-30 | $-0.00B | $-0.01B | 34.29% |
| 2017-03-31 | $-0.00B | $-0.01B | 50.00% |
| 2016-12-31 | $-0.00B | $-0.01B | 57.14% |
| 2016-09-30 | $-0.00B | $-0.01B | 64.00% |
| 2016-06-30 | $-0.01B | $-0.01B | 133.33% |
| 2016-03-31 | $-0.01B | $-0.01B | 188.24% |
| 2015-12-31 | $-0.01B | $-0.01B | 211.76% |
| 2015-09-30 | $-0.01B | $-0.00B | 266.67% |
| 2015-06-30 | $-0.01B | $-0.00B | 250.00% |
| 2015-03-31 | $-0.01B | $-0.01B | 240.00% |
| 2014-12-31 | $-0.01B | $-0.00B | 363.64% |
| 2014-09-30 | $-0.01B | $-0.00B | 628.57% |
| 2014-06-30 | $-0.01B | $-0.00B | 1800.00% |
| 2014-03-31 | $-0.01B | $-0.00B | -2000.00% |
| 2013-12-31 | $-0.01B | $0.00B | -800.00% |
| 2013-09-30 | $-0.01B | $0.00B | -466.67% |
| 2013-06-30 | $-0.01B | $0.00B | -400.00% |
| 2013-03-31 | $-0.01B | $0.00B | -400.00% |
| 2012-12-31 | $-0.00B | $0.00B | -400.00% |
| 2012-09-30 | $-0.01B | $0.00B | -480.00% |
| 2012-06-30 | $-0.01B | $0.00B | -3200.00% |
| 2012-03-31 | $-0.01B | $0.00B | -2800.00% |
| 2011-12-31 | $-0.01B | $0.00B | -2800.00% |
| 2011-09-30 | $-0.00B | $-0.00B | inf% |
| 2011-06-30 | $-0.00B | $0.00B | -266.67% |
| 2011-03-31 | $-0.00B | $0.00B | -1200.00% |
| 2010-12-31 | $-0.01B | $0.00B | 1000.00% |
| 2010-09-30 | $-0.01B | $0.00B | 160.00% |
| 2010-06-30 | $-0.01B | $-0.00B | 103.70% |
| 2010-03-31 | $-0.01B | $-0.00B | 80.00% |
| 2009-12-31 | $-0.01B | $-0.01B | 47.62% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.006B | $0.000B |
| GUIDED THERAPEUTICS, Inc. is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tests. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are available immediately. GT also owns technology for measuring substances in interstitial fluid, a secondary circulatory system in the body that surrounds the cells. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $184.227B | 24.12 |
| Stryker (SYK) | United States | $125.123B | 29.97 |
| Medtronic (MDT) | Ireland | $108.470B | 15.35 |
| Boston Scientific (BSX) | United States | $106.878B | 34.04 |
| EssilorLuxottica (ESLOY) | France | $97.379B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.753B | 0.00 |
| Haleon (HLN) | United Kingdom | $37.899B | 27.67 |
| ResMed (RMD) | United States | $31.876B | 29.93 |
| Terumo (TRUMY) | Japan | $25.923B | 36.61 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.029B | 15.99 |
| Koninklijke Philips (PHG) | Netherlands | $24.906B | 19.30 |
| Baxter (BAX) | United States | $18.798B | 13.37 |
| Insulet (PODD) | United States | $12.214B | 64.13 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.833B | 0.00 |
| Demant (WILYY) | Denmark | $10.525B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.980B | 23.77 |
| BellRing Brands (BRBR) | United States | $7.521B | 40.44 |
| Lantheus Holdings (LNTH) | United States | $5.235B | 13.05 |
| Haemonetics (HAE) | United States | $4.794B | 24.52 |
| Perrigo (PRGO) | Ireland | $4.444B | 12.71 |
| GN Store Nord (GNNDY) | Denmark | $4.368B | 24.53 |
| Prestige Consumer Healthcare (PBH) | United States | $3.475B | 16.43 |
| Envista Holdings (NVST) | United States | $3.265B | 13.48 |
| QuidelOrtho (QDEL) | United States | $2.842B | 10.32 |
| Green Thumb Industries (GTBIF) | United States | $2.777B | 88.00 |
| Neogen (NEOG) | United States | $2.604B | 25.04 |
| TG Therapeutics (TGTX) | United States | $2.502B | 70.39 |
| ICU Medical (ICUI) | United States | $2.436B | 18.18 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.255B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $1.961B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.772B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.666B | 48.83 |
| InMode (INMD) | Israel | $1.481B | 7.88 |
| National Vision Holdings (EYE) | United States | $1.402B | 43.66 |
| Owens & Minor (OMI) | United States | $1.395B | 12.14 |
| AdaptHealth (AHCO) | United States | $1.364B | 10.26 |
| Warby Parker (WRBY) | United States | $1.257B | 0.00 |
| Canopy Growth (CGC) | Canada | $1.037B | 0.00 |
| AtriCure (ATRC) | United States | $0.994B | 0.00 |
| MacroGenics (MGNX) | United States | $0.980B | 0.00 |
| Evolus (EOLS) | United States | $0.833B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.817B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.754B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.691B | 14.97 |
| Quanterix (QTRX) | United States | $0.651B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.638B | 14.99 |
| Jin Medical (ZJYL) | China | $0.561B | 0.00 |
| Valneva SE (VALN) | France | $0.537B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.514B | 0.00 |
| PetIQ (PETQ) | United States | $0.502B | 18.73 |
| Surmodics (SRDX) | United States | $0.463B | 29.01 |
| Biote (BTMD) | United States | $0.448B | 4.26 |
| ZimVie (ZIMV) | United States | $0.430B | 26.33 |
| OraSure Technologies (OSUR) | United States | $0.420B | 6.95 |
| Aurora Cannabis (ACB) | Canada | $0.368B | 0.00 |
| Zynex (ZYXI) | United States | $0.350B | 47.83 |
| Viemed Healthcare (VMD) | United States | $0.318B | 31.46 |
| Cerus (CERS) | United States | $0.300B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.280B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.257B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.244B | 15.09 |
| Veru (VERU) | United States | $0.239B | 0.00 |
| Omeros (OMER) | United States | $0.216B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.206B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.192B | 0.00 |
| High Tide (HITI) | Canada | $0.173B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.172B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.168B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.147B | 74.00 |
| Jushi Holdings (JUSHF) | United States | $0.143B | 0.00 |
| InterCure (INCR) | Israel | $0.142B | 24.00 |
| FitLife Brands (FTLF) | United States | $0.129B | 20.70 |
| Cellectar Biosciences (CLRB) | United States | $0.123B | 0.00 |
| MariMed (MRMD) | United States | $0.113B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.110B | 0.00 |
| Fonar (FONR) | United States | $0.103B | 8.86 |
| Brainsway (BWAY) | Israel | $0.096B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.095B | 0.00 |
| Chimerix (CMRX) | United States | $0.085B | 0.00 |
| Safety Shot (SHOT) | United States | $0.068B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.066B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.057B | 3.74 |
| Apyx Medical (APYX) | United States | $0.049B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.048B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.046B | 0.00 |
| Bright Green (BGXX) | United States | $0.041B | 0.00 |
| ImmuCell (ICCC) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.51 |
| Modular Medical (MODD) | United States | $0.035B | 0.00 |
| Exagen (XGN) | United States | $0.024B | 0.00 |
| Nephros (NEPH) | United States | $0.023B | 0.00 |
| Flora Growth (FLGC) | United States | $0.022B | 0.00 |
| Agape ATP (ATPC) | $0.021B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.017B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.016B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.010B | 72.73 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.007B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |